Should off-label drug use be off-the-table?

Journal of Pediatric Endocrinology and Metabolism

Volumn 20, Issue 2, 2007, Pages 171-172

  Rivkees, Scott A ^a,b  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; CERIVASTATIN; RECOMBINANT GROWTH HORMONE; ROFECOXIB; ROSUVASTATIN; SIBUTRAMINE; TROGLITAZONE; TROVAFLOXACIN;

BODY HEIGHT; BREAST CANCER; CHILD CARE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; OBESITY; OFF LABEL DRUG USE; PATENT; PHARMACEUTICAL CARE; PRESCRIPTION; SHORT STATURE; TURNER SYNDROME; UNSPECIFIED SIDE EFFECT; ADOLESCENT; CHILD; DRUG LABELING; DRUG MANUFACTURE; DRUG THERAPY; ECONOMICS; EUROPE; LEGAL ASPECT; PRESCHOOL CHILD; RARE DISEASE; UNITED STATES;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG INDUSTRY; DRUG LABELING; DRUG THERAPY; EUROPE; HUMANS; ORPHAN DRUG PRODUCTION; RARE DISEASES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34247127451     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (6)

1. Playing Down the Risks of a Drug. New York Times, December 19, 2006.
2. Eli Lilly Said To Play Down Risk of Top Pill. New York Times, December 17, 2006.
3. Drug Files Show Maker Promoted Unapproved Use. New York Times, December 18, 2006.
4. Maker of Growth Hormone Feels Long Arm of Law. FDA Consumer 1999; Vol. 33: no. 5.
5. Best Pharmaceuticals for Children Act, January 4, 2002 (Public Law No. 107-109).
6. http://energycommerce.house.gov/108/Hearings/02102005hearing1433/ Wolfe.pdf